Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150733 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02150733 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 29 participants.
The verdict
NCT02150733, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, Phase 1 study to evaluate the impact of hepatic impairment on the pharmacokinetics of Tivantinib in cancer subjects with varying degrees of hepatic function, from normal to severely impaired.
Interventions
- DRUG Tivantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02150733
The ClinicalTrials.gov registry entry for NCT02150733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tivantinib is the first listed.
NCT02150733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02150733 about?
NCT02150733 is a clinical study titled "Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment". This is a multi-center, open-label, Phase 1 study to evaluate the impact of hepatic impairment on the pharmacokinetics of Tivantinib in cancer subjects with varying degrees of hepatic function, from normal to severely impaired.
What is the current status of trial NCT02150733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02150733?
The interventions under investigation include: Tivantinib (DRUG).
Who is sponsoring clinical trial NCT02150733?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.